Revance Therapeutics (NASDAQ:RVNC) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report report published on Sunday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on the company. HC Wainwright reissued a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a research report on Friday, November 8th. Barclays dropped their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a report on Monday, December 23rd. Mizuho decreased their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a report on Tuesday, December 10th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $8.39.

Revance Therapeutics Trading Down 1.7 %

NASDAQ RVNC opened at $3.41 on Friday. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $7.59. The stock’s 50-day moving average price is $3.86 and its two-hundred day moving average price is $4.51. The company has a market cap of $355.97 million, a PE ratio of -1.77 and a beta of 0.86.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The company had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $67.73 million. Research analysts forecast that Revance Therapeutics will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Exome Asset Management LLC bought a new stake in shares of Revance Therapeutics in the 3rd quarter valued at about $1,804,000. Oddo BHF Asset Management Sas acquired a new position in Revance Therapeutics during the third quarter worth $3,763,000. Virtu Financial LLC bought a new position in shares of Revance Therapeutics in the 3rd quarter valued at about $120,000. Wellington Management Group LLP acquired a new position in shares of Revance Therapeutics during the 3rd quarter worth approximately $2,315,000. Finally, State Street Corp increased its holdings in Revance Therapeutics by 6.6% during the third quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock worth $12,632,000 after buying an additional 150,323 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.